Cecilia Qi, vice president and general manager of Pharma and Vaccines for GlaxoSmithKline China

As one of the first multinational pharmaceutical companies entering China, our confidence and resolution to uplift China strategy has been further strengthened, envisioning a more open, collaborative, inclusive and innovative future.

A new chapter has been unveiled in China as the country announced its 14th Five-year Plan aiming to build a moderately prosperous society in all respects, with people’s health and happiness as the fundamentals. This will definitely spur unprecedented opportunities for the healthcare industry. With such great opportunities, GlaxoSmithKline continues to bring the most cutting-edge products to the CIIE, such as a number of first-in-class innovative products as well as products that Chinese patients urgently need, covering critical therapeutic areas such as major diseases, chronic diseases, infectious diseases and rare diseases. Thanks to the CIIE’s spillover effect, these innovative drugs benefit more Chinese patients at a quicker pace, while GSK keeps scaling up its development with "China speed".